ReviewAging and disease2025
Aging-Related Mechanisms Underlying Carcinogenesis: Therapeutic Opportunities.
Review in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TMEM72 Inhibits the proliferation by promoting cellular senescence through the activation of the P38/MAPK signaling pathway in renal cell carcinoma.Translational oncology · 2026Article
- Exercise, Cellular Senescence, and Cancer: Novel Perspectives on Functional Aging Through Block Strength Training in Older Adults-A Narrative Review.Biomedicines · 2026Review
- Integrating single-cell and spatial transcriptomics with pan-cancer bulk sequencing identifies OSR2 as a multifaceted biomarker for prognosis and tumor immunity.Discover oncology · 2026Article
- RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a gradual loss of tissue homeostasis that leads to impaired physiological organ functions and constitutes a major risk factor for cancer initiation and progression. Despite advances in anti-tumor therapies, cancer remains the second leading cause of death worldwide. The rising incidence of cancer is intimately associated with increased lifespan and the growing proportion of older adults, with 64% of cancers diagnosed in people aged 60 and above. Mechanisms underlying aging include accumulation of somatic mutations, deficient DNA damage repair machinery, telomere shortening, enhanced genomic instability, epigenetic alterations, loss of heterochromatin, chronic low-grade inflammation, mitochondrial dysfunction, cellular senescence and its associated secretory phenotype, stem cell exhaustion, aberrant intercellular communications, remodeling of extracellular matrix and microenvironment, impaired nutrient sensing and alterations in the proteome. Additionally, dysregulation of the circadian clock, the endocannabinoid system and the microbiota may also play important roles. Given that many of these processes are also crucial for cancer development, it is widely admitted that aging and cancer are tightly interconnected. Consequently, many therapies aimed at delaying or mitigating aging, such as physical exercise, specific dietary regimens, chronotherapy, epigenetic drugs and senotherapeutics, might also prevent or retard cancer development and progression and reduce the side effects of cancer therapies. However, special caution must be taken in older cancer patients due to their comorbidities and possible frailty, selecting specific patients' treatments and balancing the extended survival with the preservation of independence and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.